Home › Agent Hub › Agent Tools › Part D coverage by drug › Ingrezza
Agent Tools
Ingrezza is a brand of valbenazine. What agents check before quoting it: how many 2026 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.
In 2026, 2,733 of 5,496 Medicare Part D and Medicare Advantage drug plans (49.7%) list Ingrezza on their formulary, across 210 of 328 formularies. The most common placement is tier 5 (2,569 plans, 94% of those covering it). 2,634 of the covering plans require prior authorization (96.4%), 0 step therapy and 2,568 a quantity limit.
43 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $0, 43 of them $0; 2,690 charge coinsurance instead — median 26% of the drug's cost. Once a member's out-of-pocket drug spending reaches $2,100 in 2026, covered drugs cost $0 for the rest of the year.
2025: 3,010 of 5,631 plans covered it (53.5%); 2026: 2,733 of 5,496 (49.7%).
Of 4,368 plans offered in both years, 122 added it to the formulary and 94 dropped it.
Among plans covering it both years, 88 moved it to a higher tier and 3 to a lower one; 0 added prior authorization and 0 removed it.
Medicare Part D paid for 259,827 30-day fills of Ingrezza in 2024 for about 32,161 enrollees, at an average total cost of $7,334.31 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).
Price Ingrezza and the rest of a client's list on every plan in their county.
Estimate Ingrezza costs by plan
Free tools for licensed insurance agents. Data from CMS public files; verify with plan documents before advising a client.
Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 09/16/2026). CMS formulary data.